NZ716896A - Methods for treating conditions associated with masp-2 dependent complement activation - Google Patents
Methods for treating conditions associated with masp-2 dependent complement activation Download PDFInfo
- Publication number
- NZ716896A NZ716896A NZ716896A NZ71689614A NZ716896A NZ 716896 A NZ716896 A NZ 716896A NZ 716896 A NZ716896 A NZ 716896A NZ 71689614 A NZ71689614 A NZ 71689614A NZ 716896 A NZ716896 A NZ 716896A
- Authority
- NZ
- New Zealand
- Prior art keywords
- masp
- complement activation
- complement
- dependent
- methods
- Prior art date
Links
- 230000024203 complement activation Effects 0.000 title abstract description 8
- 230000001419 dependent effect Effects 0.000 title abstract description 6
- 102100026046 Mannan-binding lectin serine protease 2 Human genes 0.000 abstract description 6
- 101710117460 Mannan-binding lectin serine protease 2 Proteins 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract 3
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 102000000989 Complement System Proteins Human genes 0.000 abstract 1
- 108010069112 Complement System Proteins Proteins 0.000 abstract 1
- 229940124073 Complement inhibitor Drugs 0.000 abstract 1
- 102000004856 Lectins Human genes 0.000 abstract 1
- 108090001090 Lectins Proteins 0.000 abstract 1
- 230000000735 allogeneic effect Effects 0.000 abstract 1
- 238000003776 cleavage reaction Methods 0.000 abstract 1
- 239000004074 complement inhibitor Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 abstract 1
- 239000002523 lectin Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 230000007017 scission Effects 0.000 abstract 1
- 210000000130 stem cell Anatomy 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000004154 complement system Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Discloses the use of a MASP-2 inhibitory agent which inhibits MASP-2-dependent complement activation in the manufacture of a medicament for treating or reducing the severity of post stem cell transplant thrombotic microangiopathy (TMA) in a subject receiving an allogeneic hematopoietic stem cell transplant. The MASP-2 inhibitory agent is an anti-MASP-2 monoclonal antibody, or fragment thereof that specifically binds to a portion of SEQ ID NO:6 and selectively inhibits MASP-2-dependent lectin pathway complement activation without substantially inhibiting the C1q-dependent classical complement pathway. Optionally adapted for administration in conjunction with a terminal complement inhibitor that inhibits cleavage of complement protein C5.
Description
PATENTS FORM NO. 5 Our ref: FIP237154NZPR
Divisional ation out of NZ 629683
NEW ZEALAND
PATENTS ACT 1953
COMPLETE ICATION
Methods for treating conditions associated with MASP-2 dependent complement
activation
We, Omeros Corporation, of 201 Elliott Avenue West, Seattle, 98119, Washington, United
States of America; and University of Leicester, of University Road, Leicestershire, LE1
7RH, United Kingdom hereby declare the invention, for which we pray that a patent may be
granted to us and the method by which it is to be performed, to be ularly described in and
by the following statement:
(followed by page 1a)
METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2
DEPENDENT COMPLEMENT ACTIVATION
STATEMENT REGARDING SEQUENCE LISTING
The sequence listing associated with this application is provided in text format in lieu
of a paper copy and is hereby incorporated by reference into the ication. The name of
the text file containing the sequence listing is MP_1_0179_US_SequenceListing_20131017;
The file is 110 KB, was d on October 17, 2013 and is being submitted via b
with the filing of the specification.
BACKGROUND
The complement system provides an early acting ism to initiate, amplify and
orchestrate the immune response to microbial infection and other acute insults
(M.K. Liszewski and J.P. Atkinson, 1993, in Fundamental Immunology, Third Edition,
edited by W.E. Paul, Raven Press, Ltd., New York), in humans and other vertebrates. While
complement activation provides a valuable first-line defense against potential ens, the
activities of complement that e a protective immune response can also represent a
potential threat to the host (K.R. Kalli, et al., Springer Semin. Immunopathol. 15 :417-431,
1994; B.P. Morgan, Eur. J. Clinical Investig. 24 :219-228, 1994). For example, C3 and C5
proteolytic products recruit and activate neutrophils. While indispensable for host defense,
activated neutrophils are indiscriminate in their release of destructive s and may
cause organ damage. In addition, complement activation may cause the deposition of lytic
complement components on nearby host cells as well as on microbial targets, resulting in
host cell lysis.
The complement system has also been implicated in the enesis of numerous
acute and chronic disease states, ing: myocardial infarction, stroke, ARDS,
reperfusion injury, septic shock, capillary leakage following l burns,
(followed by page 2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ748316A NZ748316A (en) | 2013-10-17 | 2014-09-01 | Methods for treating conditions associated with masp-2 dependent complement activation |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361892283P | 2013-10-17 | 2013-10-17 | |
| NZ629683A NZ629683B (en) | 2013-10-17 | 2014-09-01 | Methods for treating conditions associated with masp-2 dependent complement activation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ716896A true NZ716896A (en) | 2022-04-29 |
Family
ID=55587925
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ716896A NZ716896A (en) | 2013-10-17 | 2014-09-01 | Methods for treating conditions associated with masp-2 dependent complement activation |
| NZ748316A NZ748316A (en) | 2013-10-17 | 2014-09-01 | Methods for treating conditions associated with masp-2 dependent complement activation |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ748316A NZ748316A (en) | 2013-10-17 | 2014-09-01 | Methods for treating conditions associated with masp-2 dependent complement activation |
Country Status (1)
| Country | Link |
|---|---|
| NZ (2) | NZ716896A (en) |
-
2014
- 2014-09-01 NZ NZ716896A patent/NZ716896A/en unknown
- 2014-09-01 NZ NZ748316A patent/NZ748316A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ748316A (en) | 2022-12-23 |
| NZ629683A (en) | 2016-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | PNPASE regulates RNA import into mitochondria | |
| Silva et al. | Delimiting the origin of a B chromosome by FISH mapping, chromosome painting and DNA sequence analysis in Astyanax paranae (Teleostei, Characiformes) | |
| Kerry et al. | Selective inhibition of RNA polymerase I transcription as a potential approach to treat African trypanosomiasis | |
| De Muylder et al. | A Trypanosoma brucei kinesin heavy chain promotes parasite growth by triggering host arginase activity | |
| Guilliams et al. | African trypanosomiasis: naturally occurring regulatory T cells favor trypanotolerance by limiting pathology associated with sustained type 1 inflammation | |
| PE20170140A1 (en) | METHODS FOR TREATING CANCER WITH TIGIT INHIBITORS AND AGENTS AGAINST CANCER | |
| Siddle et al. | A tale of two tumours: comparison of the immune escape strategies of contagious cancers | |
| Rajaram et al. | Redesigned TetR-aptamer system to control gene expression in Plasmodium falciparum | |
| Begnini et al. | Auxotrophic recombinant Mycobacterium bovis BCG overexpressing Ag85B enhances cytotoxicity on superficial bladder cancer cells in vitro | |
| Hammam et al. | Wharton’s jelly-derived mesenchymal stem cells combined with praziquantel as a potential therapy for Schistosoma mansoni-induced liver fibrosis | |
| Bhaskaran et al. | Breaking Caenorhabditis elegans the easy way using the Balch homogenizer: an old tool for a new application | |
| Jezek et al. | The histone methyltransferases Set5 and Set1 have overlapping functions in gene silencing and telomere maintenance | |
| Gozzini et al. | Butyrates, as a single drug, induce histone acetylation and granulocytic maturation: possible selectivity on core binding factor-acute myeloid leukemia blasts | |
| Damm et al. | Epidermal NLRP10 contributes to contact hypersensitivity responses in mice | |
| Fernández-Álvarez et al. | TRAIL-producing NK cells contribute to liver injury and related fibrogenesis in the context of GNMT deficiency | |
| BR112021024080A2 (en) | rnai constructs to inhibit scap expression and methods of using them | |
| MX2020006012A (en) | High mobility group box-1 (hmgb1) irna compositions and methods of use thereof. | |
| Li et al. | Heat shock protein 32/heme oxygenase‐1 protects mouse Sertoli cells from hyperthermia‐induced apoptosis by CO activation of s GC signalling pathways | |
| Gomes et al. | Increasing in cysteine proteinase B expression and enzymatic activity during in vitro differentiation of Leishmania (Viannia) braziliensis: First evidence of modulation during morphological transition | |
| Koziel et al. | The Janus face of a-toxin: a potent mediator of cytoprotection in staphylococci-infected macrophages | |
| Nakai et al. | Ouro proteins are not essential to tail regression during Xenopus tropicalis metamorphosis | |
| Widdison et al. | Early response of bovine alveolar macrophages to infection with live and heat-killed Mycobacterium bovis | |
| NZ716896A (en) | Methods for treating conditions associated with masp-2 dependent complement activation | |
| ATE534288T1 (en) | DILUTION OF GENETIC CHARACTERISTICS | |
| MX2020009072A (en) | Compositions and methods for inhibiting gys2 expression. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 6 YEARS UNTIL 01 SEP 2024 BY AJ PARK Effective date: 20220819 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 SEP 2025 BY COMPUTER PACKAGES INC Effective date: 20240817 |